Related Experiment Video
Updated: Jan 9, 2026
Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
Senescence-Primed Ferroptosis Enabled by a Metal-Organic Framework Nanoplatform for Enhanced Cancer Therapy
Zeyuan Yang1, Yang Peng1, Jie Zang2
1Department of General Dentistry II, Peking University School and Hospital of Stomatology & National Center for Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Biomaterials and Digital Medical Devices, Beijing 100081, China.
Abstract:
Inhibition of cyclin-dependent kinases (CDKs) offers a promising approach for selective cancer therapy by arresting aberrant cell proliferation and inducing tumor cell senescence. However, the limited efficacy and acquired resistance resulting from primarily cytostatic rather than cytotoxic effects have hindered broader clinical applications. To overcome these limitations, we propose a senescence-primed ferroptosis strategy using a metal-organic framework (MOF)-based nanoplatform (ZPG) that codelivers CDK4/6 inhibitor (palbociclib) and ferroptosis inducer (gallium ions, Ga3+) to enhance antitumor efficacy. ZPG exhibited excellent physiological stability, improved cellular uptake, and controlled drug release. In oral squamous cell carcinoma (OSCC) cells with CDK4/6 hyperactivity, palbociclib selectively blocks cell-cycle progression and induces robust senescence, leading to downregulation of antiferroptosis factors (GPX4 and GSH) and upregulation of pro-ferroptosis factors (ACSL4 and Fe2+ accumulation). Such redox reprogramming compromises cellular antioxidant defenses and promotes lipid peroxidation, thereby sensitizing senescent cells to ferroptosis. Meanwhile, Ga3+ mimics Fe3+ in protein binding and disrupts iron metabolism, further amplifying ferroptotic stress and promoting selective ferroptosis in senescent tumor cells. Leveraging ZPG for the codelivery of therapeutic agents, the synergistic mechanism resulted in markedly enhanced antitumor efficacy both in vitro and in vivo, with minimal off-target toxicity. Collectively, the ZPG-enabled senescence-primed ferroptosis strategy provides a promising and mechanistically rational approach for improving cancer therapy.
Insights
This study introduces a novel nanoplatform (ZPG) that combines a cell-cycle inhibitor (palbociclib) and gallium ions to induce ferroptosis in senescent cancer cells, enhancing antitumor efficacy with reduced toxicity.
Area of Science:
- Oncology
- Nanomedicine
- Biochemistry
Background:
- Cyclin-dependent kinase (CDK) inhibitors show promise in cancer therapy by halting cell proliferation and inducing senescence.
- Limited efficacy and resistance due to cytostatic effects hinder clinical use of CDK inhibitors.
- A strategy is needed to convert cytostatic effects into cytotoxic outcomes for improved cancer treatment.
Purpose of the Study:
- To develop a metal-organic framework (MOF)-based nanoplatform (ZPG) for codelivering a CDK4/6 inhibitor and gallium ions.
- To investigate a senescence-primed ferroptosis strategy to enhance antitumor efficacy in oral squamous cell carcinoma (OSCC).
- To evaluate the synergistic effects of combined therapy on cancer cell death and therapeutic outcomes.
Main Methods:
- ZPG nanoplatform synthesized for codelivery of palbociclib and gallium ions (Ga3+).
- Assessment of ZPG stability, cellular uptake, and drug release kinetics.
- Investigation of palbociclib-induced senescence and its effect on ferroptosis regulators (GPX4, GSH, ACSL4).
- Evaluation of Ga3+-mediated iron metabolism disruption and ferroptosis induction in senescent OSCC cells.
- In vitro and in vivo studies to determine antitumor efficacy and toxicity.
Main Results:
- ZPG demonstrated good stability, cellular uptake, and controlled release of palbociclib and Ga3+.
- Palbociclib induced senescence in OSCC cells, downregulating antiferroptosis factors and upregulating pro-ferroptosis factors.
- Ga3+ amplified ferroptotic stress by disrupting iron metabolism, leading to selective ferroptosis in senescent cells.
- The ZPG-enabled senescence-primed ferroptosis strategy showed significantly enhanced antitumor efficacy in vitro and in vivo with minimal toxicity.
Conclusions:
- The ZPG nanoplatform effectively combines cell-cycle inhibition and ferroptosis induction for synergistic cancer therapy.
- Senescence-primed ferroptosis represents a promising and mechanistically rational approach to overcome limitations of CDK inhibitors.
- This strategy offers a potential new avenue for improving cancer treatment outcomes by converting cytostatic effects into cytotoxic ones.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:16Necrosis
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...